We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Sponsor content
5 result(s) found, displaying 1 to 5
-
Australian public assessment report (AusPar)New AusPAR for Rholistiq (belumosudil) for the treatment of patients with chronic graft-versus-host disease aged 12 years and older.
-
Prescription medicine decision summaryTGA decision: Rholistiq (belumosudil mesilate) is approved to treat chronic graft-versus-host disease (GVHD)
-
Prescription medicine registrationActive ingredients: belumosudil mesilate.
-
-